Levothyroxine Sodium Tablets
Subpotent Drug
Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.
14,535 recalls, newest first.
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Subpotent Drug
Lack of Assurance of Sterility: Affected product may exhibit an open or incomplete seal on the packaging of the applicator
Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications
Lack of Assurance of Sterility
Presence of precipitate
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI).
Presence of Foreign Tablets/Capsules
Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).
SubPotent Drug: low pH and significantly reduced assay (~0.6% vs expected ~6 7%).